TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Clinical trial NCT04518852 · COMPLETED

Trial details

NCT number: NCT04518852
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Liver Neoplasms Digestive System Neoplasms Sorafenib Molecular Mechanisms of Pharmacological Action Liver Diseases Antineoplastic Agents Protein Kinase Inhibitors

Start date: 2020-09-14
Primary completion: 2022-07-31
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.